TD vaccine was produced on semi industrial scale at National Institute of Vaccine Da Lat – Nha Trang. 13 lots of biopreparations had met the safe and efficace criterion of WHO and of National Centre of quality control. Tetanos component reached the mean value of 157.08 IU/ml  42.36 and diphteria component – 37.00 IU/ml  9.3. The vaccine has been examining in human
Diphtheria ; Tetanus ; Diphtheria Toxoid

No abstract available.
Diphtheria ; Polyneuropathies*

The results of epidemiological surveillance showed that the incidence of diphtheria has reduced by 71% in the period of 1996 - 2001 compared with that in the period of 1991-1995, as a result of DPT immunization for children under 1 year of age in the EPI that has been accelerated since 1986. Especially, since 1994 the DPT immunization coverage has been sustained at greater than 90%. In the period of 1991-2002 the incidence of diphtheria was high in some provinces of the northern region. The disease occurred all year round, however, the incidences were highest in December and lowest in February, case mortality inhabitants rate recorded was 10.8%.
Diphtheria ; diagnosis

The IVAC in-house reference for diphtheria vaccine has an average dry weight of 51.18 mg/ampoule, 2.85% moisture content (standard 3%). The reference vaccine kept at -20oC for 60 months still remains stable with 333.84 IU/ampoule. Kept at 37oC for 1, 2, 4, 6 and 8 weeks still remains stable. Potency of diphtheria component of DPT vaccine controlled by in-house reference vaccine and international standard vaccine gave the same results.
Diphtheria Toxoid ; vaccines

Absorbed DTP vaccines in the same Lot (produced by IVAC, Nha Trang) were kept at 4°C, -5 +/-10oC, -20°C on 2, 3 and 6 hours. After being thawed completely, the vaccine containers were vigorously shaken and the contents were examined for physical changes. The results showed that the containers kept at 4oC had no physical changes; the containers kept at -5 +/-10oC, 20°C for 6 hours had significant changes such as agglomeration, floccules or granular matter, and sedimented rapidly. It is suggested that structure of aluminum adjuvant in DTP vaccine is changed. The containers kept at -5 +/-10oC, -20°C for 6 hours can be considered as the positive control and the shaking test can be used to determine the previous freezing of adsorbed DTP vaccines.
Diphtheria-Tetanus-Pertussis Vaccine ; Freezing

The Institute of Vaccine had elaborated a procedure of preapration and produced successfully a 4 component liquid vaccine of diphteria – tetanos – coqueluche and meningitis (DTP-Hib). The quality have reached the standards issued in European and WHO Pharmacopoeia. The procedure of preparation of DPT-Hib mixt vaccine and the preliminary procedure of its quality control were established
Vaccines ; Diphtheria ; Tetanus ; Whooping Cough

The rate of immunization was high and maintained continuously 11 years in the Northern Region. Evident, efficacy is the decreasing of incidence of EPI diseases, especially poliomyelitis, neonatal tetanus, and diphtheria. During continuous 8 years (from 1994 to 2001), there has been no wild poliovirus in the Northern Region, and the Region was certificated as polio-free in 2000. Neonatal tetanus has also been eliminated at the provincial level since 1995 and at district level since 1999. The other EPI diseases have been considerably reduced
Epidemiology ; immunization ; poliomyelitis ; Tetanus ; Diphtheria

In this study, PCR technique was used with 2 primer pairs for amplifying DNA fragments at 5’ and 3’ of the gene encoding diphteria toxine of the strains Corynebacterium diphtheriae. After the cloning and sequencing, 2 separated fragments were joined to form a complete gene. The sequence of gene was translated into protein and the results were submitted into Gene Bank Database
Diphtheria Toxin ; Genes ; Corynebacterium diphtheriae

BACKGROUND: This study was conducted to assess the immunogenicity and safety of GC1107 (adult tetanus diphtheria [Td] vaccine). The primary goal was to evaluate the non-inferiority of the immunogenicity of GC1107 compared to the control vaccine. Additionally, the safety profiles of GC1107 and the control vaccine were compared. METHODS: The subjects were adults ≥ 18 years old who were not injected with Td or adult tetanus-diphtheria-pertussis (TdaP) vaccine within the recent 5 years. A total of 253 subjects were enrolled and randomized to either the GC1107 group or the control group. For immunogenicity assessment, blood samples were collected at baseline and 28 days after vaccination and antibody titer of diphtheria and tetanus were assessed. RESULTS: The seroprotection rates of diphtheria and tetanus were 89.76% and 91.34%, respectively, in the GC1107 group, and 87.80% and 86.99% in the control group. The geometric mean titer (GMT) of the anti-diphtheria antibody increased after vaccination in both groups, showing no significant difference between the groups (P = 0.139). The anti-tetanus GMTs after vaccination also showed comparable increases in both groups, and showed no significant difference (P = 0.860). In the safety evaluation, solicited local adverse reactions occurred in 81.2% of the subjects in the GC1107 group and in 86.4% of the subjects in the control group. Solicited systemic adverse events occurred in 33.2% of the subjects in the GC1107 group and in 47.2% of the subjects in the control group, which did not reach statistical significance. CONCLUSION: This phase III study demonstrated non-inferiority in immunogenicity and comparable safety of GC1107 compared with the control Td vaccine. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02361866
Adult* ; Diphtheria* ; Humans ; Tetanus* ; Vaccination

No abstract available.
Child* ; Diphtheria-Tetanus-Pertussis Vaccine* ; Humans ; Infant*